PREVALENCE OF LINEZOLID RESISTANCE IN GRAM POSITIVE PATHOGENIC COCCI ISOLATED FROM CLINICAL SAMPLES IN A TERTIARY CARE CIVIL HOSPITAL, AHMEDABAD

S.T. SONI¹*, K.J. PATEL², R.P. RADADIYA³, V.K. PRAJAPATI⁴, D.J. MISTRY⁵, H.D. SHARMA^6
1Department of Microbiology, B. J. Medical College, Gujarat University, Ahmedabad, Gujarat, 380016, India
²Department of Microbiology, B. J. Medical College, Gujarat University, Ahmedabad, Gujarat, 380016, India
³Department of Microbiology, B. J. Medical College, Gujarat University, Ahmedabad, Gujarat, 380016, India
⁴Department of Microbiology, B. J. Medical College, Gujarat University, Ahmedabad, Gujarat, 380016, India
⁵Department of Microbiology, B. J. Medical College, Gujarat University, Ahmedabad, Gujarat, 380016, India
⁶Department of Microbiology, B. J. Medical College, Gujarat University, Ahmedabad, Gujarat, 380016, India
* Corresponding Author : drsumeetasoni@gmail.com

Received : 03-09-2021     Accepted : 26-09-2021     Published : 30-09-2021
Volume : 13     Issue : 4       Pages : 1969 - 1971
Int J Microbiol Res 13.4 (2021):1969-1971

Keywords : Linezolid resistance, Staphylococcus aureus, Enterococcus faecium, Streptococcus spp
Conflict of Interest : None declared
Acknowledgements/Funding : Authors are thankful to Department of Microbiology, B. J. Medical College, Gujarat University, Ahmedabad, Gujarat, 380016, India
Author Contribution : All authors equally contributed

Introduction: The first approved oxazolidinone group of drugs, Linezolid is nowadays have been used for multidrug resistant bacterial infection, including Staphylococci, Streptococci, Enterococci infections. Resistance to Linezolid is not common but now a days some cases of Linezolid resistance have been reported. So, this study is done to see the prevalence of Linezolid resistance in gram positive pathogenic cocci isolated from various clinical samples in tertiary care Civil Hospital, Ahmedabad. Material and Methods: The present study was conducted over a period of 20 months (January 2020 to August 2021). Various samples like blood, pus, swabs, CSF, body fluids, etc. are included in this study. From positive growth of these samples gram positive pathogenic cocci were isolated and confirmed. Antimicrobial susceptibility tests were done according to CLSI guidelines 2021. Results: Total 54266 samples were tested out of which gram-positive cocci were 5548 (10.22%). Out of these only 53 (0.95%) isolates were Linezolid resistant. The most commonly found Linezolid resistance is in Enterococcus fecium-29(54.72%). Conclusion: Linezolid which was the promising agent against multi drug resistant gram-positive cocci such as VRE, MRSA is now showing resistance. Its detection in clinical samples is necessary for deciding treatment protocols by clinicians

1. Moellering R.C. (2003) Ann Intern Med., 138(2), 135-42.
2. Food and Drug Administration. (2000) FDA approves Zyvox, the first anti- microbial drug in a new class. 18 April 2000.
3. Meka V.G., Gold H.S. (2004) Clin Infect Dis., 39(7), 1010-5.
4. Doern C.D., Park J.Y., Gallegos M., Alspaugh D., Burnham C.A. (2016) J Clin Microbiol., 54(5), 1289-1294.
5. Eustice D.C., Feldman P.A., Zajac I., Slee A.M. (1988) Antimicrob Agents Chemother., 32, 1218-22.
6. Lin A.H., Murray R.W., Vidmar T.J., Marotti K.R. (1997) Antimicrob Agents Chemother., 41, 2127-31.
7. Matassova N.B., Rodnina M.V., Endermann R., et al. (1999) RNA, 5, 939-46.
8. Shinabarger D.L., Marotti K.R., Murray R.W., et al. (1997) Antimicrob Agents Chemother, 41, 2132-6.
9. Fines M., Leclercq R. (2000) J Antimicrob Chemother., 45, 797-802.
10. Tsiodras S., Gold H.S., Sakoulas G., et al. (2001) Lancet, 2001, 358, 207-8.
11. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C. (2001) Lancet, 2001, 358, 207-208.
12. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M. (2003) J Antimicrobial Chemotherapy, 51, 186-188.
13. Meka V.G., Pillai S.K., Sakoulas G., Wennersten C., Venkataraman L. (2004) J Infect Dis., 2004, 190, 311-317.
14. Schwarz S., Werckenthin C., Kehrenberg C. (2000) Antimicrob Agents Chemother., 2000, 44, 2530-2533.
15. Livermore D.M., Warner M., Mushtaq S., North S., Woodford N. (2007) Antimicrob Agents Chemother., 2007, 51, 1112-1114.
16. Livermore D.M., Mushtaq S., Warner M., Woodford N. (2009) J Antimicrobial Chemotherapy, 63, 713-715.
17. Bender J., Cattoir V., Hegstad K., et al (2018) Drug Resist Updates, 40, 25-39.
18. Lincopan N., de Almeida L.M., de Araújo M.R.E., Mamizuka E.M. (2009) Int J Antimicrob Agents, 2009, 34, 281-282.
19. Kehrenberg C., Schwarz S., Jacobsen L., Hansen L.H., Vester B. (2005) Mol Microbiol., 57, 1064-1073.
20. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. (2006) Antimicrob Agents Chemother., 50, 2500-2505.
21. Locke J.B., Hilgers M., Shaw K.J. (2009) Antimicrob Agents Chemother., 53, 5275-5278.
22. Locke J.B., Hilgers M., Shaw K.J. (2009) Antimicrob Agents Chemother., 53, 5265-5274.
23. Almeida L.M., Araújo M.R., Sacramento A.G., Pavez M., Souza A.G. (2013) Antimicrob Agents Chemother., 57, 4082-4083.
24. Flamm R., Mendes R., Hogan P., et al (2016) Antimicrob Agents Chemother., 60(4), 2273-2280.
25. Kelly S., Collins J., Maguire M., et al (2008) J Antimicrob Chemother., 61(4), 901-907.
26. Gupta V., Garg S., Jain R., Garg S., Chander J. (2012) Asian Pacific Journal of Tropical Medicine, 5(10), 2012, 837-838.